Dec 12, 2022 / 09:30PM GMT
Operator
Greetings and welcome to Harpoon Therapeutics interim results and corporate update call. (Operator Instructions) And as a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Julie Eastland, Chief Executive Officer of Harpoon Therapeutics.
Julie Eastland - Harpoon Therapeutics, Inc. - CEO
Hi. Thanks so much, and thanks to everybody on the call for joining us today for the update. In today's update we will be talking about our plans and our program, and making forward-looking statements. We do refer you to our security filings including both the financial and the risks associated with these statements that you can find in our security filings from the SEC.
So I'm pleased today to introduce Dr. Luke Walker, who's our Chief Medical Officer. He's on the phone today, and he will walk through a review of the HPN217, our BCMA targeted TriTAC program, a review of the interim data that we presented at ASH in poster form yesterday. And we'll do a progress update on HPN328 as well.
So for those of you
Harpoon Therapeutics Inc HPN217 Interim Results Transcript
Dec 13, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers